In fact, it has been shown that the cross-talk between ERα, HER2, and EGFR plays an important role in tamoxifen-induced proliferation in p53-mutated (or downregulated) breast cancer cells (Fernandez-Cuesta et al., 2011). The gene discussed is ERBB2; the disease is breast cancer.